Skip to main content

Table 4 Grade three or four treatment-related non-haematological adverse events by number of patients 1

From: PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Adverse event

Group A2(n=9)

Group B3(n=6)

Group C4(n=21)

Group D5(n=6)

Gd 3

Gd 4

Gd 3

Gd 4

Gd 3

Gd 4

Gd 3

Gd 4

Fatigue

2

-

-

-

6

-

2

2

Febrile neutropenia

-

3

2

-

1

-

-

-

Alopecia

-

-

-

-

3

-

-

-

Nausea

1

-

-

-

1

-

-

-

Respiratory infection

-

-

1

-

-

-

1

-

Vomiting

-

-

-

-

2

-

-

-

Anaemia

-

-

-

-

1

-

-

-

Anorexia

-

-

-

-

1

-

-

-

Dehydration

-

-

-

-

1

-

-

-

Diarrhoea

-

-

-

-

1

-

-

-

Leukopenia

1

-

-

-

-

-

-

-

QT/QTc prolongation

-

-

-

-

-

-

1

-

Weight loss

-

-

-

-

1

-

-

-

  1. 1Highest toxicity grade by CTCAE version 3.0 for each patient; 2 PR104 + gemcitabine; 3 PR104 + docetaxel 60; 4 PR104 + docetaxel 60 + GCSF; 5 PR104 + docetaxel 75 + GCSF.